Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases

    Access Status
    Fulltext not available
    Authors
    Pirillo, A.
    Catapano, A.
    Norata, Giuseppe
    Date
    2016
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Pirillo, A. and Catapano, A. and Norata, G. 2016. Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases. Current Medicinal Chemistry. 23 (10): pp. 983-999.
    Source Title
    Current Medicinal Chemistry
    ISSN
    0929-8673
    School
    School of Biomedical Sciences
    URI
    http://hdl.handle.net/20.500.11937/56131
    Collection
    • Curtin Research Publications
    Abstract

    © 2016 Bentham Science Publishers. Circulating levels of cholesterol are derived from either endogenous production or intestinal absorption of dietary and biliary cholesterol. Niemann-Pick C1-Like 1 (NPC1L1) is a transmembrane protein that plays a key role in the intestinal absorption of cholesterol by facilitating its uptake through vesicular endocytosis. NPC1L1 is the molecular target of ezetimibe which binds its extracellular loop and inhibits sterol absorption without affecting the absorption of other molecules. Ezetimibe significantly reduces plasma levels of total and low density lipoprotein cholesterol (LDL-C) as monotherapy or when added to statins, the association with a low dose of statin is of particular interest for patients experiencing statin-related side effects. The recent results of the IMPROVE-IT study, which evaluated the cardiovascular effect of ezetimibe added to simvastatin therapy in subjects who had had an acute coronary syndrome and with LDL-C levels within the recommended range, showed that a further LDL-C lowering reduced the incidence of cardiovascular events. To date, ezetimibe represents the only inhibitor of NPC1L1 available for clinical use, however, novel aminos- lactam ezetimibe derivatives have been synthesized and their efficacy to inhibit NPC1L1 protein and decrease plasma cholesterol levels is under evaluation.

    Related items

    Showing items related by title, author, creator and subject.

    • Dietary phytosterols modify the sterols and fatty acid profile in a tissue-specific pattern
      Alhazzaa, Ramez; Oen, J.; Sinclair, A. (2013)
      Phytosterol consumption reduces the absorption of dietary cholesterol and can alter the tissue fatty acid composition. The effects of manipulating sterol and phospholipid fatty acid profile by increasing levels of ...
    • Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
      Grigore, L.; Raselli, S.; Garlaschelli, K.; Redaelli, L.; Norata, Giuseppe; Pirillo, A.; Catapano, A. (2013)
      Background/Aim: Statin treatment improves endothelial function. It is matter of debate, however, if this effect of statins is due to their action on low-density lipoprotein cholesterol (LDL-C) or to other non-lipidic ...
    • Nutritional and pharmacological regulation of cerebral capillary function
      Pallebage-Gamarallage, Menuka Madhavi Somapala (2012)
      Alzheimer’s disease (AD) is the most common cause of dementia pathologically characterised by neurovascular inflammation, extracellular proteinaceous deposits enriched in amyloid-β (Aβ) and formation of neurofibrillar ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.